# Seasonal Malaria Chemoprevention With Dihydroartemisin Piperaquin vs. Sulfadoxine-pyrimethamin+Amodiaquin

> **NCT04149106** · PHASE3 · UNKNOWN · sponsor: **University Clinical Research Center, Mali** · enrollment: 4556 (estimated)

## Conditions studied

- Malaria,Falciparum

## Interventions

- **DRUG:** Sulfadoxine pyrimethamine + Amodiaquin
- **DRUG:** Dihydroartemisinin piperaquin

## Key facts

- **NCT ID:** NCT04149106
- **Lead sponsor:** University Clinical Research Center, Mali
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-12-30
- **Target enrollment:** 4556 (ESTIMATED)
- **Last updated:** 2023-03-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04149106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04149106, "Seasonal Malaria Chemoprevention With Dihydroartemisin Piperaquin vs. Sulfadoxine-pyrimethamin+Amodiaquin". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04149106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*